CompletedNCT00714688
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
Medication studyAges 18–65Multiple countriesADHD
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Antwerp, Belgium · Brussels, Belgium and 40 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateFebruary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 279
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Switzerland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00714688
- Official title
Show the full official title
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder
Recruitment & locations
CompletedAntwerp, Belgium · Brussels, Belgium · Kortenberg, Belgium
39 more locations
- Mechelen, Belgium
- Mons, Belgium
- Aarhus, Denmark
- Hjørring, Denmark
- Holstebro, Denmark
- Helsinki, Finland
- Oulu, Finland
- Pori, Finland
- Montpellier, France
- Nice, France
- Paris, France
- Ahrensburg, Germany
- Aschaffenburg, Germany
- Berlin, Germany
- Düsseldorf, Germany
- Essen, Germany
- Freiburg im Breisgau, Germany
- Mannheim, Germany
- München, Germany
- Saarbrücken, Germany
- Würzburg, Germany
- Nijmegen, Netherlands
- The Hague, Netherlands
- Bryne, Norway
- Oslo, Norway
- Ottestad, Norway
- Skien, Norway
- Barcelona, Spain
- Madrid, Spain
- Huddinge, Sweden
- Linköping, Sweden
- Lund, Sweden
- Malmö, Sweden
- Örebro, Sweden
- Uppsala, Sweden
- Basel Bs, Switzerland
- Zurich, Switzerland
- Cambridge, United Kingdom
- Swansea, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedEUCTR 2011-000210-19
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
Belgium, Denmark, Germany, + 1 other
CompletedEUCTR 2005-003002-28
A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg...
Germany